Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Aamdal

Showing results (21-30 of 64) with videos related to

Pageof 7
Sort By:
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|January 5, 2002
[Diagnosis and treatment of oral precancerous lesions]J Sudbø, T Warloe, S Aamdal, et al.
Journal of Experimental Therapeutics & Oncology|May 1, 1996
Transcapillary forces of the subcutaneous tissue in patients treated with interleukin-2 and alpha-interferon: no capillary protein leak syndrome?K A Semb, S Aamdal, S D Fosså, et al.
Melanoma Research|January 26, 1999
Clinical experience of fotemustine, cisplatin and high dose tamoxifen in patients with metastatic malignant melanomaK A Semb, S Aamdal, T Bohmann, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|November 25, 2000
Immunobead-based detection and characterization of circulating tumor cells in melanoma patientsO Fodstad, R Faye, H K Høifødt, et al.
International Journal of Cancer|March 15, 1988
A new experimental metastasis model in athymic nude mice, the human malignant melanoma LOXO Fodstad, S Aamdal, M McMenamin, et al.
Cancer Chemotherapy and Pharmacology|January 27, 2000
Phase I trial with weekly EO9, a novel bioreductive alkylating indoloquinone, by the EORTC Early Clinical Study Group (ECSG)S Aamdal, B Lund, I Koier, et al.
The American Journal of Pathology|September 1, 1992
Detection of bone marrow metastases in small cell lung cancer patients. Comparison of immunologic and morphologic methodsK Beiske, A T Myklebust, S Aamdal, et al.
Anti-Cancer Drugs|December 5, 1998
Zilascorb(2H), a low-toxicity protein synthesis inhibitor that exhibits signs of anticancer activity in malignant melanomaK A Semb, S Aamdal, E Mette, et al.
Anti-Cancer Drugs|March 1, 1997
Zilascorb(2H), a new reversible protein synthesis inhibitor: clinical study of an oral preparationK A Semb, O Fodstad, B Klem, et al.
The British Journal of Cancer. Supplement|June 1, 1991
Selection of anti-SCLC antibodies for diagnosis of bone marrow metastasisA T Myklebust, K Beiske, A Pharo, et al.
Pageof 7

Showing results (21-30 of 64) with videos related to

Sort By:
Pageof 7
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|January 5, 2002
[Diagnosis and treatment of oral precancerous lesions]J Sudbø, T Warloe, S Aamdal, et al.
Journal of Experimental Therapeutics & Oncology|May 1, 1996
Transcapillary forces of the subcutaneous tissue in patients treated with interleukin-2 and alpha-interferon: no capillary protein leak syndrome?K A Semb, S Aamdal, S D Fosså, et al.
Melanoma Research|January 26, 1999
Clinical experience of fotemustine, cisplatin and high dose tamoxifen in patients with metastatic malignant melanomaK A Semb, S Aamdal, T Bohmann, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|November 25, 2000
Immunobead-based detection and characterization of circulating tumor cells in melanoma patientsO Fodstad, R Faye, H K Høifødt, et al.
International Journal of Cancer|March 15, 1988
A new experimental metastasis model in athymic nude mice, the human malignant melanoma LOXO Fodstad, S Aamdal, M McMenamin, et al.
Cancer Chemotherapy and Pharmacology|January 27, 2000
Phase I trial with weekly EO9, a novel bioreductive alkylating indoloquinone, by the EORTC Early Clinical Study Group (ECSG)S Aamdal, B Lund, I Koier, et al.
The American Journal of Pathology|September 1, 1992
Detection of bone marrow metastases in small cell lung cancer patients. Comparison of immunologic and morphologic methodsK Beiske, A T Myklebust, S Aamdal, et al.
Anti-Cancer Drugs|December 5, 1998
Zilascorb(2H), a low-toxicity protein synthesis inhibitor that exhibits signs of anticancer activity in malignant melanomaK A Semb, S Aamdal, E Mette, et al.
Anti-Cancer Drugs|March 1, 1997
Zilascorb(2H), a new reversible protein synthesis inhibitor: clinical study of an oral preparationK A Semb, O Fodstad, B Klem, et al.
The British Journal of Cancer. Supplement|June 1, 1991
Selection of anti-SCLC antibodies for diagnosis of bone marrow metastasisA T Myklebust, K Beiske, A Pharo, et al.
Pageof 7